Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 3, 1996, Pages 251-261

  Peterson, W L ^a,c   Ciociola, A A ^b   Sykes, D L ^b   Mcsorley, D J ^b   Webb, D D ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PLACEBO; RANITIDINE BISMUTH CITRATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DUODENUM ULCER; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT PEPTIC ULCER; TASTE DISORDER; ULCER HEALING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RANITIDINE; RECURRENCE;

EID: 0029900572     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-0673.1996.00251.x     Document Type: Article

References (60)

1. Megraud F, LaMouliatte H. Helicobacter pylori and duodenal evidence suggesting causation. Dig Dis Sci 1992; 37: 769-72.
2. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med 1992; 116: 705-8.
3. Patchett S, Beattie S, Leen E, Keane C, O'Morain C. Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol 1992; 87: 24-30.
4. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
5. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomachs of patients with gastritis and peptic ulceration. Lancet 1984; 8390: 1311-4.
6. Peterson WL, Barnett CC, Evans DJ, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88: 2038-43.
7. Tytgat GNJ, Noach LA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin N Am 1993; 22: 127-39.
8. Borody TJ, George LL, Brandi S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991; 86: 1154-7.
9. Louw JA, Falck V, van Rensburg C, et al. Distribution of Helicobacter pylori colonization and associated gastric inflammatory changes: difference between patients with duodenal and gastric ulcers. J Clin Pathol 1993; 46: 754-6.
10. Simon B, Cremer M, Dammann HG, et al. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer: a multicentre trial in Europe. Scand J Gastroenterol 1987; 22 (Suppl. 136): 61-70.
11. Pace F, Colombo E, Ferrara A, et al. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration. Am J Gastroenterol 1988; 83: 643-5.
12. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
13. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993; 328: 349-50. (Editorial; Comment.)
14. Tytgat GNJ, Axon ATR, Dixon MF, et al. Working Party Reports of the World Congresses in Gastroenterology 1990: 36-45.
15. O'Riordan T, Mathai E, Tobin E, et al. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut 1990; 31: 999-1002.
16. deBoer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 1993-7.
17. Wilhelmsen I, Weberg R, Berstad K, et al. Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. Hepatogastroenterology 1994; 41: 43-7.
18. Wilhelmsen I, Berstad A. Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994; 29: 974-9.
19. Bell GD, Powell K, Burridge SM, et al. Experience with triple anti Helicobacter pylori eradication therapy side effects and the importance of testing the pretreatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-35.
20. Marshall BJ, Hoffman SR, McCallum RW. Incidence of side effects during bismuth subsalicylate and antibiotic therapy for H. pylori (HP). Gastroenterology 1991; 100: A117.
21. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-81.
22. Glupczynski Y, Burrette A, DeKoster E, et al. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976-7.
23. 2-antagonist activity, on 24-hour intragastric acidity. Aliment Pharmacol Ther 1991; 5: 481-90.
24. Logan RPH, Gummett PA, Misiewicz JJ, et al. The efficacy of ranitidine bismuth citrate (GR 122311X) in the treatment of Helicobacter pylori infection. Gastroenterology 1992; 102 (part 2): A114.
25. Hudson N, Murray FE, Cole AT, et al. Ranitidine bismuth citrate and aspirin-induced gastric mucosal injury. Aliment Pharmacol Ther 1993; 7: 515-21.
26. Wilder-Smith CH, Smith JTL, Bettschen HU, Lettis S, Merki HS. Cytoprotective effect of ranitidine bismuth citrate against aspirin-induced upper GI tract mucosal damage. Gastroenterology 1993; 104: A224 (Abstract).
27. Stables R, Campbell CJ, Clayton NM, et al. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther 1993; 7: 237-46.
28. Fraser AG, Lam WM, Luk YW, et al. Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens. Gut 1993; 34: 338-42.
29. Sytnik B, Kovacs TOG, Mertz H, et al. Oral GR122311X (ranitidine bismuth citrate) new potent inhibitor of meal-stimulated acid secretion in both H. pylori positive and H. pylori negative volunteers. Gastroenterology 1992; 104: A202 (Abstract).
30. Butruk E, Ching CK, Schutze K, Duggan AE. GR122311X (ranitidine bismuth citrate) with amoxicillin for the treatment of duodenal ulcer. Gastroenterology 1995; 108 (4): A64 (Abstract).
31. Tanaka S, Nishizaki Y, Paulsen G, et al. Ranitidine bismuth citrate protects gastric mucosa from indomethacin-induced injury in rats by altering the acid permeability of gastric mucus. Gastroenterology 1995; 108 (4): A235.
32. Tarnawski A, Tanoue K, Lee J, et al. Ranitidine bismuth citrate protects gastric microvascular endothelium and extracellular matrix from ethanol injury. Gastroenterology 1995; 108: A237 (Abstract).
33. Wyeth JW, Pounder RE, DeKoster E, et al. CR122311X (ranitidine bismuth citrate) with antibiotics for the eradication of Helicobacter pylori. Gastroenterology 1994; 106: A212 (Abstract).
34. Bardhan KD, Dekkers CPM, Nowak A, et al. GR122311X (ranitidine bismuth citrate) a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Ther 1995; 9: 497-506.
35. Ciociola AA, Koch KM, McSorley D, et al. Safety and pharmacokinetics of ascending oral doses of GR122311X (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology 1992; 102: A51 (Abstract).
36. Bailey RJ, Marlicz K, Rosch W, et al. GR122311X (ranitidine bismuth citrate) a new drug for the treatment of gastric ulcer. Gastroenterology 1995; 108: A51 (Abstract).
37. Ciociola AA, Koch KM, McSorley D, et al. Safety and pharmacokinetics of chronic oral dosing of GR122311X (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology 1992; 102: A50 (Abstract).
38. McLaren A, McDowell SR, Bagshaw JA, et al. GR122311X and clarithromycin against Helicobacter. Am J Gastroenterol 1994; 89: 1382 (Abstract).
39. McLaren A, McDowell SR. GR122311X can significantly reduce the emergence of H. pylori strains resistant to antibiotics. Gut 1995; 37 (Suppl. 1): A62 (Abstract).
40. Megraud F, Bonnet F, Garnier M, Lamouliatte H. Characterization of 'Campylobacter pyloridis' by culture, enzymatic profile, and protein content. J Clin Microbiol 1985; 22: 1007-10.
41. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Human Pathol 1994; 25: 221-6.
42. Kelkar R, Desai D, Swaroop VS, et al. Comparison of sensitivity and specificity of three different methods for the detection of Helicobacter pylori infection. Am J Gastroenterol 1990; 85: 1654. (Letter: Comment.)
43. Rudensky B, Braverman DZ, Dollberg L, Isacsohn M, Jacobsohn WZ. Comparison of different tests for Helicobacter pylori. Am J Gastroenterol 1990; 85: 325-6. (Letter.)
44. Schnell GA, Schubert TT. Usefulness of culture, histology, and urease testing in the detection of Campylobacter pylori. Am J Gastroenterol 1989; 84: 133-7.
45. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double blind trial of duodenal relapse after eradication of Campylobacter pylori. Lancet 1988; ii: 1437-42.
46. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann Intern Med 1991; 115: 266-9.
47. Bardhan KD, Dallaire C, Eisold H, Duggan AE. The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin. Gut 1995; 37 (Suppl. 1): A5 (Abstract).
48. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860-4.
49. Pounder RE, Bailey R, Louw JA, et al. GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of Helicobacter pylori. Gut 1995; 37 (1): A42 (Abstract).
50. Hirschowitz BI, Mohnen J, Shaw S. High recurrence rate of duodenal ulcer despite H. pylori eradication in a clinical subset - rapidly recurring peptic ulcer (RRPU). Gastroenterology 1994; 106 (4): A94 (Abstract).
51. Hirschowitz BJ, Lanas A. Intractable and recurrent postsurgical peptic ulceration is due to aspirin (ASA) abuse, much of it surreptitious. Gastroenterology 1992; 102 (4): A84 (Abstract).
52. Jyotheeswaren S, Penmetsa P, Wadhera A, Ona FV, Chey WY. Prevalence of Helicobacter pylori in peptic ulcer patients in Rochester, New York. Gastroenterology 1995; 108 (4): A126.
53. Schnell GA, Schubert TT. Usefulness of culture, histology and urease testing in the detection of Campylobacter pylori. Am J Gastroenterol 1989; 84: 133-7.
54. Price AB, Levi J, Dolby JM, et al. Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. Gut 1985; 26: 1183-8.
55. Steer HW. Surface morphology of the gastroduodenal mucosa in duodenal ulceration. Gut 1984; 25: 1203-10.
56. Schubert TT, Bologna SD, Nensey Y, et al. Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 1993; 94: 413-8.
57. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol 1993; 28 (Suppl. 196): 34-7.
58. Burette A, Glupczynski Y, De Prez C. Evaluation of various multi-drug eradication regimens for Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 817-23.
59. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
60. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9.